ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma

Lymphocyte nadir predicts tumor response and survival in locally advanced rectal cancer after neoadjuvant chemoradiotherapy: Immunologic relevance

(2019) Hao Liu et al.   RADIOTHERAPY AND ONCOLOGY

ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment

(2019) Magnus T. Dillon et al.   CLINICAL CANCER RESEARCH

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma

(2019) Changhoon Choi et al.   WORLD JOURNAL OF GASTROENTEROLOGY

ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation

(2019) Luciana Rodrigues Gomes et al.   Cell Death & Disease

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

(2019) Willemijn S. M. E. Theelen et al.   JAMA Oncology

Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition

(2019) Jared M. Newton et al.   Journal for ImmunoTherapy of Cancer

Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders

(2019) Ling Chen et al.   Cellular & Molecular Immunology

The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models

(2019) Antje M. Wengner et al.   MOLECULAR CANCER THERAPEUTICS

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

(2019) Rina Hui et al.   LANCET ONCOLOGY

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell–dependent antitumor activity following radiation

(2018) Frank P. Vendetti et al.   JOURNAL OF CLINICAL INVESTIGATION

ATR inhibition is a promising radiosensitizing strategy for triple negative breast cancer

(2018) Xinyi Tu et al.   MOLECULAR CANCER THERAPEUTICS

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

(2017) Narek Shaverdian et al.   LANCET ONCOLOGY

Chasing the thermodynamical noise limit in whispering-gallery-mode resonators for ultrastable laser frequency stabilization

(2017) Jinkang Lim et al.   Nature Communications

Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model

(2017) Kyoung-Jin Kim et al.   Oncotarget

PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy

(2016) Abul Azad et al.   EMBO Molecular Medicine

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

Phase 2 Study of Combined Sorafenib and Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma

(2014) Shang-Wen Chen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma

(2013) Alexis Bujold et al.   JOURNAL OF CLINICAL ONCOLOGY

Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization

(2012) Jin-Kyu Kang et al.   CANCER

Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation

(2012) A. Gupta et al.   JOURNAL OF IMMUNOLOGY

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity

(2011) B. C. Burnette et al.   CANCER RESEARCH

Radiation-inducible PTEN expression radiosensitises hepatocellular carcinoma cells

(2010) Yong Zhang et al.   INTERNATIONAL JOURNAL OF RADIATION BIOLOGY

Radiation Enhances Regulatory T Cell Representation

(2010) Evelyn L. Kachikwu et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients

(2010) Julien Fourcade et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment

(2009) Y. Lee et al.   BLOOD

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY